Skip to main content
NCBI home page
Memórias do Instituto Oswaldo Cruz logoLink to Memórias do Instituto Oswaldo Cruz
. 2025 Oct 20;120:e240272. doi: 10.1590/0074-02760240272

The impact of probiotic administration on experimental in vitro and in vivo infection by Trypanosoma cruzi

Denise da Gama Jaén Batista, Lara Calheiros Missagia, Kelly Cristina Demarque, Gabriel Melo de Oliveira, Marcos Meuser Batista, Maria de Nazaré Correia Soeiro 1,+
PMCID: PMC12543362  PMID: 41124405

Abstract

BACKGROUND

Chagas disease (CD) caused by Trypanosoma cruzi has limited therapy. Probiotics sustain healthy microbiota, playing roles in biological events.

OBJECTIVES

Our aim was to determine the impact of probiotics on T. cruzi infection in vitro and in mouse acute experimental models.

METHODS

The multi strain - PB8 and the Lactobacillus rhamnosus (LR) were orally administered [106-109 colony-forming units (CFU)] for seven days prior to mice infection followed for 14 daily administrations. Peritoneal mouse macrophages (PMM) were obtained from mice treated with 109 probiotics one day before collection and infected in vitro with or not benznidazole (BZ).

FINDINGS

LR and PB8 reduced by 44-87% and 23-16% the parasitaemia peak in male and female mice, respectively, but did not protect against mortality. Histopathology showed mild reduction in cardiac nests due to probiotics’ administration. PB8 and LR suppressed the parasite infection of PMM by 24 and 26%, reaching 65 and 42% of declines, respectively when 3% thioglycolate was performed. PB8 increased BZ activity at 1 µM, reaching 40% of parasitism’ declines compared to BZ alone (25%). No gender difference was noticed during probiotic in vivo administration.

MAIN CONCLUSIONS

The results point to the potential of a combined therapeutic approach for CD, using probiotics and BZ.

Key words: Lactobacillus rhamnosus, multi strain PB8, Trypanosoma cruzi, experimental chemotherapy, benznidazole

Chagas disease (CD) is caused by the protozoan parasite Trypanosoma cruzi. CD is currently endemic in 21 Latin American countries with more than 6 million people infected, and around 10,000 deaths per year. 1 However, it is still commonly associated with poor and rural regions. 2 The principal route of T. cruzi infection is via infected faeces of haematophagous triatomine bugs, 2 , 3 although transmission can also occur orally, via the placental route during pregnancy or childbirth; by blood transfusion and organ transplantation; or even, from laboratory accidents. 4

The infection period and the symptoms may vary depending on the route of penetration, the inoculum, the strain, and the patient’s condition. 5 , 6 The disease has two consecutive clinical steps: a short acute phase followed by the chronic stage. 7 The acute phase is characterised by detectable parasitaemia, but most carriers are asymptomatic, and less than 5% die due to encephalomyelitis or severe heart failure and due to cardiac arrest. 7 , 1

Due to immune and inflammatory responses, parasitism is controlled, but not eliminated, and the infected individuals migrate to the chronic phase. Most will remain asymptomatic throughout their lives, in the clinical stage called the indeterminate form of the disease. However, after years, 30-40% may develop symptoms related to cardiac and/or digestive disorders, leading to severe loss of the organs functionally. 7

Currently, the therapy is based on two old medications, nifurtimox (Nif, LAMPIT®, Bayer) and benznidazole (BZ/LAFEPE, Abarax®, ELEA and BZ/Chemo Research, Exeltis). 8 Both achieve satisfactory results during the acute phase but require prolonged use and induce side effects that result in abandonment of treatment. Besides, both drugs present lower cure rates in the later chronic phase. 9 , 10

The microbiota is composed of diverse microorganisms, including commensals, symbiotics and even pathogenic microbes. 11 In humans, microbiota acts on different metabolic pathways including nutritional metabolism, immune response, drug interactions besides impacting disease outcomes. 11 , 12 , 13 Its high diversity and density are influenced by different environmental, physiological, and behavioural factors such as habits and food sources, gender, age, physical activity, among others. 14 , 15

Thus, microbial communities can also influence the susceptibility or resistance profile to an infectious agent. 16 For example, diseases caused by protozoa and helminths can be aggravated or their pathological consequences reduced according to the intestinal microbiota. 11 , 17 Experimental data showed that it may influence and provide protection against infections caused by bacteria spp. such as Listeria monocytogenes, Salmonella typhimurium, Salmonella enteritidis and Escherichia coli, 18 by virus such as coronavirus 19 and by protozoan parasites like T. cruzi. 20 , 21 It has been reported that mouse experimental infection by T. cruzi is more severe in germ-free animals, resulting in higher parasitaemia and greater mortality. 20 Also, the oral or intraperitoneal administration of Lactobacillus casei to female Swiss mice decreases T. cruzi parasitaemia. 21

Probiotics are live microorganisms that may promote healthy microbiota, maintaining a balance among the different axis (intestinal, skin, oral and genital mucosa) and promoting health benefits for the host. 11 Thus, it has been suggested that these elements could contribute as co-therapies against parasitic infections, being a low-cost and non-invasive therapeutic approach, not inducing adverse effects. 22

In the present study, we investigated through in vitro and in vivo assays the possible impact of probiotics administration during murine experimental acute T. cruzi infection and its potential effect during the therapy with BZ.

MATERIALS AND METHODS

Probiotics and reference drug - A multi strain probiotic (eight strains composed of: Lactobacillus acidophilus LA-14, Bifidobacterium lactis BL-04, Lactobacillus plantarum LP-115, Lactobacillus salivarius LS-33, Bifidobacterium bifidum BB-06, Bifidobacterium longum, Lactobacillus rhamnosus GG (DSM 33156) - LGG ® and Lactobacillus casei LC-1110) were acquired from Nutrition Now and Hypera and diluted in phosphate buffered saline (PBS). The Lactobacillus rhamnosus GG (DSM 33156) - LGG ® was purchased by Mantecorp Farmasa. BZ, the reference drug for CD, was purchased from LAFEPE.

Animals - Male and female Swiss mice (18 - 21 g) were obtained from the Institute of Science and Technology in Biomodels (ICTB-Fiocruz), housed in a maximum of six animals per box and maintained at 20 to 24ºC under a cycle light/dark 12/12 h. Animals were kept in a specific pathogen-free (SPF) and received sterilised water and food ad libitum [ration Nuvilab, Quimtia composed by corn, soybean meal, wheat bran, calcium carbonate, dicalcium phosphate, sodium chloride (common salt), vitamin A, vitamin D3, vitamin E, vitamin K3, vitamin B1, vitamin B2, vitamin B6, vitamin B12, niacin, calcium pantothenate, folic acid, biotin, choline chloride, iron sulphate, manganese monoxide, zinc oxide, copper sulphate, calcium iodate, sodium selenite, cobalt sulphate, lysine and methionine] . The animals were acclimatised for seven days before the experiments.

Parasites - Bloodstream trypomastigote (BT) forms of T. cruzi [Y strain - discrete typing units II (DTU II)] were obtained from the blood of T. cruzi-infected mice at the peak of parasitaemia using 3.8% of sodium citrate as anticoagulant. 23

Mammalian cells - Peritoneal mouse macrophages (PMM) were obtained from Male Swiss mice previously stimulated or not with 3% thioglycolate, 96 h before PMM obtention. 24 Briefly, mice stimulated or not by thioglycolate, were treated orally with probiotics (109) 24 h before the obtention of PMM. Briefly, 10 mL of RPMI medium was injected into the peritoneum of the euthanised animal. The peritoneal cells were subsequently collected using a syringe, the suspension quantified in a Neubauer chamber for adjusting the cellular density to be seeded in 96-well plates (105 cells per well) or 24 wells plates (3x 105 cells). After 2 h of plating, fresh RPMI medium supplemented with 10% foetal bovine serum (FBS), 2%. L-glutamine and 1% penicillin and streptomycin were added and the PMM incubated at 37ºC (5% CO2). 24

In vitro activity on intracellular forms of T. cruzi (Y strain) in PMM obtained from animals stimulated or not with 3% thioglycolate and treated with probiotics - PMM from mice stimulated or not with thioglycolate and treated or not for 24 h with 109 LR and PB8 were obtained, seeded as above described and infected for another 24 h at 37ºC with BT of T. cruzi (Y strain, under parasite: host cell ratio 10:1). After the infection of cells, the cultures were washed to remove parasites that did not internalise and incubated or not for 48-96 h with different concentrations (1 and 10 µM) of the antiparasitic compound. Alternatively, PMM were incubated in vitro for 2 and 24 h with probiotics, rinsed with PBS and subsequently infected for 24 h with BT forms (ratio of 10 parasites to 1 cell). The cultures were rinsed with PBS, fixed with Bouin, stained with Giemsa. 25 Subsequently, the percentage of infected host cells, as well as the number of parasites per cell were quantified under a light microscope to determine the infection index, which represents the multiplication of these two factors. 25

All assays were performed in duplicates at least three times.

In vivo assays: infection and treatment - Male and female Swiss mice were treated by gavage for seven consecutive days with 106 - 109 colony-forming units (CFU) of Lactobacillus rhamnosus (LR) and PB8 (109 CFU). After treatment, mice were infected intraperitoneally (i.p.) with 104 BT forms (Y strain) of T. cruzi. Then, probiotic administration was sustained for another 14 days, totalising 21 days of treatment. In all assays, control groups included a group infected and treated only with vehicle and a group infected and treated with the reference drug (BZ, at optimal dose - 100 mg/kg/day, given by gavage at 5-14-day post-infection - dpi).

Parasitaemia, weight curve and mortality rate - Parasitaemia was measured according to the Pizzi-Brener methodology (Brener, 1962). From the 5th (parasitaemia onset) up to 16 dpi, parasitaemia analysis was performed individually by light microscopy observation of the number of parasites in 5 μL of blood collected from the tail vein 26 Mortality was assessed daily and expressed as a percentage of accumulated mortality. 26 , 27

Histopathological analysis - At the 10 dpi, the surviving animals were euthanised using an overdose of isoflurane and confirmed by the absence of respiratory movement (apnoea), absence of heartbeat (asystole), loss of colour of the mucous membranes, and loss of brightness and moisture of the corneas, as observed by the veterinarian responsible for the procedure. Then, the heart collected and fixed in formalin (10%). 26 The samples were cleaved and processed for paraffin inclusion. The obtained sections (7 µm) were then stained using haematoxylin and eosin dyes, as reported. 26 The number of amastigote nests in at least 50 fields (100 x magnification in light microscope) per slide from ≥ 3 mice per group (four sections from each animal) was quantified. Inflammation was assessed regarding the presence of: (i) only inflammatory infiltrates classified as “mononuclear infiltrate”; and (ii) cell infiltrates associated to other tissular alterations such as degeneration, congestion, and necrosis, classified as “mononuclear inflammation”. The degree of the tissular lesions was determined based on the extent and severity of inflammation was classified scoring grades 0-3: (a) Grade 0: minimal or no tissular alterations and the lack of infiltration or inflammation; (b) Grade 1: mild tissular changes, with the presence of infiltration or inflammation restricted to small areas (only in the atrial cardiac region and focal, multifocal or diffuse); (c) Grade 2: moderate tissular changes with infiltration and/or inflammation covering most of the atrial and part of the ventricular heart regions in a multifocal pattern and multifocal and (d) Grade 3: severe tissular changes, with infiltration and/or inflammation largely found in the samples covering most of the atrial and ventricular cardiac region in a multifocal or diffuse manner.

Statistical analysis - The analysis was performed using Analysis of variance (ANOVA) with a significance level of p ≤ 0.05 [95% confidence interval (CI)].

Ethical statement - All procedures were carried out under the biosafety guidelines of the Oswaldo Cruz Institute (IOC/ Fiocruz), and all animal procedures complied with the guidelines established by the FIOCRUZ Committee of Ethics for the Use of Animals, resolution (CEUA numbers: L038-2017 and L-038/2017-A4).

RESULTS

The administration of increasing CFU (106 - 108) of LR showed decreases (no statistical significance - p > 0.05) in the parasitaemia peak (at 8 dpi) of Swiss male mice acutely infected with T. cruzi, reaching 36% at 108 CFU. As positive control, the treatment of the infected animals for five days with the reference drug (BZ at 100 mg/kg/day) cleared the parasitaemia (Fig. 1A). Regarding mortality rates, only BZ gave 100% animal survival (Fig. 1B).

Fig. 1: the effect of 106-108 colony-forming units (CFU) Lactobacillus rhamnosus (LR) in Swiss male mice before experimentally infection by Trypanosoma cruzi (Y strain). The graph depicts the parasitaemia curve (A) and cumulative mortality (B) (n = 5). In all groups treated with probiotics, there was no statistical significance (p > 0.05) as compared to the reference group (vehicle-treated animals).

Fig. 1:

Open in a new tab

Swiss male mice treated with higher probiotic concentration (LR 109 CFU) showed a significant decrease (51%, p = 0.039) in the mean number of circulating parasites in the peak (8 dpi) as compared to the vehicle group (Fig. 2A). Importantly, two out of five animals treated with probiotics showed negative parasitaemia at the 8 dpi (Fig. 2B). A head-to-head comparison using a multi strain probiotic (PB8 - 109 CFU) also demonstrated parasitaemia decline (23%, p = 0.25), being less expressive than LR (Fig. 2A).

Fig. 2: the effect of 109 colony-forming units (CFU) Lactobacillus rhamnosus (LR) and PB8 oral administration in Swiss male mice before experimentally infection by Trypanosoma cruzi (Y strain). The graph depicts the parasitaemia curve (A) and the parasite load at the parasitaemia peak (8 dpi) (B) (n = 5). Statistical analysis compared to the reference group (vehicle-treated animals): *p = 0.039 and **p = 0.25.

Fig. 2:

Open in a new tab

In the female Swiss mice group only PB8 (109 CFU) mildly reduced (p = 0.44) the parasitaemia peak by 15.92% (Fig. 3).

Fig. 3: the effect of 109 colony-forming units (CFU) Lactobacillus rhamnosus (LR) and PB8 on the parasitaemia peak (8 dpi) in Swiss female mice experimentally infected by Trypanosoma cruzi (Y strain). The vehicle group received only saline before infection (n = 5). In all groups treated with probiotics, there was no statistical significance (p > 0.05) as compared to the reference group (vehicle-treated animals).

Fig. 3:

Open in a new tab

As LR was more effective than PB8, a further assay was performed to compare the probiotic activity at parasitaemia as well as in the heart parasitism. Swiss male mice treated with LR achieved 87% (p = 0.038) of parasitaemia decline at the 8 dpi (Fig. 4). The heart histopathology at the 10 dpi demonstrated a 12% (p = 0.74) decrease in the number of cardiac nests as compared to vehicle group, while BZ group reached 85% (p = 0.0069) (Fig. 5). The analysis of cardiac inflammatory profile demonstrated that only animals treated with BZ were scored as “grade 1” (inflammatory infiltrate). Animals that received LR (except one scored as grade 1) showed cardiac mononuclear inflammation. Vehicle-treated animals showed both grades 1 and 2 (Table).

Fig. 4: the effect of 109 colony-forming units (CFU) Lactobacillus rhamnosus (LR) oral administration in Swiss male mice before the experimental infection by Trypanosoma cruzi (Y strain). The graph denotes the parasitaemia curve over the days of the experiment. Statistical analysis as compared to the reference group (vehicle-treated animals): *p = 0.038.

Fig. 4:

Open in a new tab

Fig. 5: the effect on cardiac parasitism of Swiss male mice experimentally infected by Trypanosoma cruzi (Y strain). The mean number of parasite nests in cardiac samples of Swiss male mice submitted to 109 colony-forming units (CFU) Lactobacillus rhamnosus (LR) administration and then experimentally infected with T. cruzi. In parallel, T. cruzi-infected animals were treated for five consecutive days with benznidazole (BZ) (100 mg/kg/day) (n = 3). Statistical analysis as compared to the reference group (vehicle-treated animals): *p = 0.0069 and **p = 0.74.

Fig. 5:

Open in a new tab

TABLE. Histopathological analysis of heart samples from male mice treated with probiotic or benznidazole (BZ) treatment. The table depicts the degree of inflammation and infiltration profile in the heart of the studied animals’ groups.

Group Inflammatory profile * /number of animals
0 1 2 3
Vehicle 0/3 2/3 1/3 0/3
BZ 1/3 2/3 0/3 0/3
LR 109 0/2 1/2 0/2 1/2
Open in a new tab

LR: Lactobacillus rhamnosus. *Inflammatory profile scored as: (a) Grade 0: minimal or no tissular alterations and the lack of infiltration or inflammation; (b) Grade 1: mild tissular changes, with the presence of infiltration or inflammation restricted to small areas (only in the atrial cardiac region and focal, multifocal or diffuse without significant mucosal involvement in intestinal samples); (c) Grade 2: moderate tissular changes with infiltration and/or inflammation covering most of the atrial and part of the ventricular heart regions in a multifocal pattern and multifocal and/or diffuse infiltration/inflammation without significant mucosal intestinal involvement; and (d) Grade 3: severe tissular changes, with infiltration and/or inflammation largely found in the samples covering most of the atrial and ventricular cardiac region in a multifocal or diffuse manner and multifocal or diffuse involving all layers of the intestine.

Our in vivo findings encouraged us to further explore if the probiotic administration could impact the in vitro infection of PMM by T. cruzi. Our findings demonstrate that a single in vivo administration of PB8 and LR (without thioglycolate stimulation in vivo) followed by collection and infection of PMM with T. cruzi reduced the infection index by 24 and 26% (p = 0.11 and p = 0.2), respectively as compared to the administration of only TH. This decline was more evident when animals were both stimulated using thioglycolate and probiotics. The association of probiotics administration in vivo with thioglycolate stimulation reached drops of 65 and 42% for PB8 (p = 0.01) and LR (p = 0.06), respectively, as compared to PMM obtained only with thioglycolate stimulation (Fig. 6).

Fig. 6: the effect of the infection indexes of peritoneal mouse macrophages (PMM) infected by Trypanosoma cruzi (Y strain) in vitro collected from male Swiss mice previously exposed to a single dose of 109 colony-forming units (CFU) Lactobacillus rhamnosus (LR) and PB8. The graph shows the infection rate of PMM from animals also stimulated or not only with 3% thioglycolate (TH) and treated or not with the probiotics (n = 3). Statistical analysis as compared to the reference group (TH-treated animals): ****p = 0.01, **p = 0.11 and ***p = 0.2; and *p = 0.06.

Fig. 6:

Open in a new tab

Next, we checked if the probiotic administration could also impact on the antiparasitic effect of the reference drug used to treat CD. We confirmed reductions in the infection index of PMM when cells were collected from male mice exposed to PB8+TH as compared to only TH stimulation (50% decline, p = 0.044; Fig. 7).

Fig. 7: the effect of the infection index of peritoneal mouse macrophage (PMM) infected with Trypanosoma cruzi (Y strain) in vitro under incubation of benznidazole (BZ). PMM were obtained from thioglycolate (TH) stimulated animals submitted or not to 109 colony-forming units (CFU) PB8 administration, infected with T. cruzi (Y strain) and further exposed or not for 48 h to BZ at 1 µM (n = 3). Statistical analysis: *TH x TH/PB8 (p = 0.044); **TH x TH/BZ (p = 0.129) and ***TH/PB8 x TH/PB8/BZ (p = 0.0012).

Fig. 7:

Open in a new tab

When a high concentration of BZ (10 µM) was used to treat the infected-PMM cultures, no difference was achieved (data not shown). However, when a suboptimal concentration (1 µM) was assessed, a clear improvement in BZ activity was found. BZ alone at 1 µM reduced 25% (p = 0.129) the intracellular parasitism of PMM from mice stimulated with thioglycolate. PMM from PB8-treated mice stimulated by thioglycolate exposed to 1 µM BZ (TH/PB8 + BZ), displayed a statistically significant drop of 40% (p = 0.0012) in the intracellular parasitism as compared to TH/PB8 group (Fig. 7).

DISCUSSION

A large bulk of evidence suggests that microbiota plays important roles on host health, improving immunological and metabolic functions, demonstrating the potential use of probiotics. Clinical and preclinical studies report the benefits of probiotic administration as adjuvant therapy for many diseases including neuropsychiatric disorders, 28 infectious diseases 21 among others. 29 Presently, we addressed if probiotic administration in experimental mice could improve their response to control a parasitic infection caused by the intracellular protozoan T. cruzi.

Two types of probiotics were tested: a multi strain probiotic composed of eight different strains (Lactobacillus acidophilus LA-14, Bifidobacterium lactis BL-04, Lactobacillus plantarum LP-115, Lactobacillus salivarius LS-33, Bifidobacterium bifidum BB-06, Bifidobacterium longum, Lactobacillus rhamnosus and Lactobacillus casei LC-1110) comparing to the effect of a single strain (LR) present into the multi strain probiotic. Our data showed the benefit of probiotic use as adjuvant, achieving reductions in blood and cardiac parasitism of mice experimentally infected by T. cruzi. Our results support and corroborate the findings reported by Martins and colleagues using another T. cruzi strain and the administration of L. casei. 30

Our assays showed that the probiotic effect was more pronounced in male mice as compared to females. Differences related to parasitic infection and therapy susceptibility were already reported while comparing both genders during experimental mouse models of T. cruzi infection, 27 but further studies are needed as only single analysis was performed using female Swiss mice.

The drop in the parasitaemia peak observed during probiotic administration was confirmed by the histopathological analysis of cardiac samples of the surviving animals, although in a less extensive manner. This analysis validates the hypothesis that healthy microbiome helps to sustain an effective immunological response, contributing to parasitism control.

Our histopathologic analysis showed an inflammatory profile in the hearts of all animals regardless of the therapy that is due to the direct action of the parasite during the acute infection, 31 associated or not with degeneration, congestion, necrosis, and/or fibrosis. 32

The bulk of our data supports the use of probiotics as an additive element along with antiparasitic drugs. These may be different mechanisms such as substances released by probiotic microorganisms, as well as their action in the inflammatory and immune responses. 33 Literature reports on modulation of the cellular microenvironment (nutrients, mucus, receptor availability on epithelial cells, pH, tight junctions, and peristalsis, among others), production of biologically active molecules (such as bacteriocins, antibiotics, or hydrogen peroxide) with antimicrobial properties. Also, immunological modulation has been claimed due to the interaction of phagocytes such as macrophages and dendritic cells and T cells, leading to cytokine induction and/or a humoral immune response. 34

We also found that animals treated with probiotic (one single administration of 109 CFU of PB8 and LR) triggered the capacity of PMM to control in vitro infection by T. cruzi, resulting in lower infection rates. This effect was even more pronounced when mice were additionally stimulated with thioglycolate, a drug used for triggering macrophages migration into the mice peritoneum. We found that more than 60% of decreases in the parasitism rates of PMM obtained from PB8+TH stimulated mice. Also, when the reference drug for CD was added at 10 µM into the infected PMM cultures, no additional effect could be observed possibly because this concentration already corresponds to the IC90 value of BZ. 8 However, when a ten-fold lower concentration (1 µM) was used, a statistically significant decline in the infection index was observed: BZ alone resulted in 25% of decreases at 1 µM, while PMM collected from probiotic-treated and/or not TH stimulated mice and further exposed to BZ achieved > 40% of decline in the infection index.

Our results unequivocally show that probiotics can promote the action of antiparasitic agents at suboptimal doses justifying additional studies.

ACKNOWLEDGEMENTS

To Rede de Plataformas Tecnológicas da Fiocruz, IOC/Fiocruz [PlaBio RPT 11F Rio de Janeiro, Fundação Oswaldo Cruz (Fiocruz)].

Footnotes

Financial support: FIOCRUZ, CNPq, FAPERJ. MNCS is CNPq and CNE researcher.

How to cite: Batista DGJ, Missagia LC, Demarque KC, de Oliveira GM, Batista MM, Soeiro MNC. The impact of probiotic administration on experimental in vitro and in vivo infection by Trypanosoma cruzi. Mem Inst Oswaldo Cruz. 2025; 120: e240272.

REFERENCES

  • 1.WHO Chagas disease (American trypanosomiasis) 2024. https://www.who.int/health-topics/chagas-disease#tab=tab_
  • 2.Vannier-Santos MA, Brunoro GV, Soeiro MNC, De Castro SL, Menna-Barreto RFS. Parasite, compartments, and molecules: trick versus treatment on Chagas disease. Biology of Trypanosoma cruzi. 2019 [Google Scholar]
  • 3.Chagas C. Nova tripanozomiase humana Estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem. Mem Inst Oswaldo Cruz. 1909;1(2):159–218. [Google Scholar]
  • 4.Onyekwelu KC. Life cycle of Trypanosoma cruzi in the invertebrate and the vertebrate hosts. Biology of Trypanosoma cruzi. 2019 [Google Scholar]
  • 5.Coura JR. Chagas disease: what is known and what is needed - A background article. Mem Inst Oswaldo Cruz. 2007 doi: 10.1590/s0074-02762007000900018. [DOI] [PubMed] [Google Scholar]
  • 6.Rassi A, Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010;375(9723):1388–1402. doi: 10.1016/S0140-6736(10)60061-X. [DOI] [PubMed] [Google Scholar]
  • 7.Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis. 2001;1:92–100. doi: 10.1016/S1473-3099(01)00065-2. [DOI] [PubMed] [Google Scholar]
  • 8.Soeiro MNC, Sales-Junior PA, Pereira VRA, Vannier-Santos MA, Murta SMF, Sousa AS. Drug screening and development cascade for Chagas disease an update of in vitro and in vivo experimental models. Mem Inst Oswaldo Cruz. 2024;119:e240057. doi: 10.1590/0074-02760240057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Soeiro MNC. Perspectives for a new drug candidate for Chagas disease therapy. Mem Inst Oswaldo Cruz. 2022;117:e220004. doi: 10.1590/0074-02760220004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Pérez-Molina JA, Molina I. Chagas disease. Lancet. 2018;391(10115):82–94. doi: 10.1016/S0140-6736(17)31612-4. [DOI] [PubMed] [Google Scholar]
  • 11.Berg RD. The indigenous gastrointestinal microflora. Trends Microbiol. 1996;4(11):430–435. doi: 10.1016/0966-842x(96)10057-3. [DOI] [PubMed] [Google Scholar]
  • 12.Chumpitazi BP. The gut microbiome as a predictor of low fermentable oligosaccharides disaccharides monosaccharides and polyols diet efficacy in functional bowel disorders. Curr Opin Gastroenterol. 2020;36(2):147–154. doi: 10.1097/MOG.0000000000000608. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Grice EA, Segre JA. The human microbiome our second genome. Annu Rev Genomics Hum Genet. 2012;13:151–170. doi: 10.1146/annurev-genom-090711-163814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Claesson MJ, Cusack S, O'sullivan O, Greene-Diniz R, De Weerd H, Flannery EM, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci. 2011 doi: 10.1073/pnas.1000097107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A. What is the healthy gut microbiota composition A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019;7(1):14–14. doi: 10.3390/microorganisms7010014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Kamada N, Seo SU, Chen GY, Núñez G. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol. 2013;13(5):321–335. doi: 10.1038/nri3430. [DOI] [PubMed] [Google Scholar]
  • 17.Bäumler AJ, Sperandio V. Interactions between the microbiota and pathogenic bacteria in the gut. Nature. 2016;535(7610):85–93. doi: 10.1038/nature18849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Yu HS, Lee NK, Choi AJ, Choe JS, Bae CH, Paik HD. Antagonistic and antioxidant effect of probiotic Weissella cibaria JW15. Food Sci Biotechnol. 2019;28(3):851–855. doi: 10.1007/s10068-018-0519-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Infusino F, Marazzato M, Mancone M, Fedele F, Mastroianni CM, Severino P. Diet supplementation, probiotics, and nutraceuticals in SARSCoV-2 infection a scoping review. Nutrients. 2020;12(6):1718–1718. doi: 10.3390/nu12061718. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Silva ME, Evangelista EA, Nicoli JR, Bambirra EA, Vieira EC. American trypanosomiasis (Chagas' disease) in conventional and germfree rats and mice. Rev Inst Med Trop São Paulo. 1987;29(5):284–288. doi: 10.1590/s0036-46651987000500004. [DOI] [PubMed] [Google Scholar]
  • 21.Duarte-Silva E, Morais LH, Clarke G, Savino W, Peixoto C. Targeting the gut microbiota in Chagas disease what do we know so far? Front Microbiol. 2020;11:585857–585857. doi: 10.3389/fmicb.2020.585857. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Mandal S, Mondal C, Lyndem LM. Probiotics an alternative anti-parasite therapy. J Parasit Dis. 2024;48(3):409–423. doi: 10.1007/s12639-024-01680-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Meirelles MNL, Araujo-Jorge TC, Miranda CF, de Souza W, Barbosa HS. Interaction of Trypanosoma cruzi with heart muscle cells ultrastructural and cytochemical analysis of endocytic vacuole formation and effect upon myogenesis. Eur J Cell Biol. 1984;41:198–206. [PubMed] [Google Scholar]
  • 24.Santos CC, Lionel JR, Peres RB, Batista MM, da Silva PB, de Oliveira GM. In vitro, in silico, and in vivo analyses of novel aromatic amidines against Trypanosoma cruzi. Antimicrob Agents Chemother. 2018;62(2):e02205–e02217. doi: 10.1128/AAC.02205-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Guedes-da-Silva FH, Batista DGJ, Meuser MB, Demarque KC, Fulco T, de Araújo JS. In vitro and in vivo trypanosomicidal action of novel arylimidamides against Trypanosoma cruzi. Antimicrob Agents Chemother. 2016;60:2425–2434. doi: 10.1128/AAC.01667-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Batista DGJ, Silva PB, Lachter DR, Silva RS, Aucelio RQ, Louro SRW. Manganese(II) complexes with N4-methyl-4-nitrobenzaldehyde, N4-methyl-4-nitroacetofenone, and N4-methyl-4-nitrobenzophenone thiosemicarbazone investigation of in vitro activity against Trypanosoma cruzi. Polyhedro. 2010;29:2232–2238. [Google Scholar]
  • 27.Guedes-da-Silva FH, Batista DG, da Silva CF, Meuser MB, Simões-Silva MR, de Araújo JS. Different therapeutic outcomes of benznidazole and VNI treatments in different genders in mouse experimental models of Trypanosoma cruzi infection. Antimicrob Agents Chemother. 2015;59(12):7564–7570. doi: 10.1128/AAC.01294-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Lei W, Cheng Y, Gao J, Liu X, Shao L, Kong Q. Akkermansia muciniphila in neuropsychiatric disorders friend or foe? Front Cell Infect Microbiol. 2023;13:1224155–1224155. doi: 10.3389/fcimb.2023.1224155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Azad MAK, Sarker M, Li T, Yin J. Probiotic species in the modulation of gut microbiota an overview. Biomed Res Int. 2018;8:9478630–9478630. doi: 10.1155/2018/9478630. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Garfias CRB, Álvarez MCT, Gómes FM. The inoculation of Lactobacillus casei in NIH mice induces a protective response against Trypanosoma cruzi (Ninoa strain) infection. Vet México. 2008;39:39–144. [Google Scholar]
  • 31.De Alba-Alvarado MC, Torres-Gutiérrez E, Reynoso-Ducoing OA, Zenteno-Galindo E, Cabrera-Bravo M, Guevara-Gómez Y. Immunopathological mechanisms underlying cardiac damage in Chagas disease. Pathogens. 2023;12(2):335–335. doi: 10.3390/pathogens12020335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Berridge BR, Mowat V, Nagai H, Nyska A, Okazaki Y, Clements PJ, et al. Non-proliferative and proliferative lesions of the cardiovascular system of the rat and mouse. J Toxicol Pathol. 2016 doi: 10.1293/tox.29.3S-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Travers MA, Florent I, Kohl L, Grellier P. Probiotics for the control of parasites an overview. J Parasitol Res. 2011;2011:610769–610769. doi: 10.1155/2011/610769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Eslami M, Bahar A, Keikha M, Karbalaei M, Kobyliak NM, Yousefi B. Probiotics function and modulation of the immune system in allergic diseases. Allergol Immunopathol (Madr) 2020;48(6):771–788. doi: 10.1016/j.aller.2020.04.005. [DOI] [PubMed] [Google Scholar]

Articles from Memórias do Instituto Oswaldo Cruz are provided here courtesy of Instituto Oswaldo Cruz

RESOURCES